Literature DB >> 21060341

Chemotherapy-induced peripheral neurotoxicity.

Guido Cavaletti1, Paola Marmiroli.   

Abstract

Chemotherapy-induced peripheral neurotoxicity (CIPN) is a common, potentially severe and dose-limiting adverse effect of cancer treatment; however, the effects of CIPN on the daily life of individuals are not completely understood. CIPN can be induced by several types of drugs that are widely used in the treatment of solid and hematological malignancies. Our knowledge of the mechanisms underlying CIPN is incomplete, but structural properties of the various neurotoxic compounds might contribute to variations in the pathogenetic mechanisms of damage, in addition to the type of neurotoxicity, severity of the clinical condition, and incidence of CIPN. No drugs capable of preventing the occurrence of CIPN or ameliorating its long-term course are available, and chemotherapy schedule modification is often required to limit its severity, which could potentially prevent patients from receiving the most effective treatment for cancer. Moreover, symptomatic therapy is often largely ineffective in reducing CIPN symptoms. In this Review, the mechanistic and clinical aspects of this unpredictable condition are considered, along with the controversial aspects of CIPN, including the onset mechanisms associated with the different drug types, assessment of the patient's condition, and the current status of neuroprotection and treatment options.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21060341     DOI: 10.1038/nrneurol.2010.160

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN: 1759-4758            Impact factor:   42.937


  133 in total

1.  Intraepidermal nerve fiber density in rat foot pad: neuropathologic-neurophysiologic correlation.

Authors:  Giuseppe Lauria; Raffaella Lombardi; Monica Borgna; Paola Penza; Roberto Bianchi; Costanza Savino; Annalisa Canta; Gabriella Nicolini; Paola Marmiroli; Guido Cavaletti
Journal:  J Peripher Nerv Syst       Date:  2005-06       Impact factor: 3.494

2.  Evidence that nerve growth factor promotes the recovery of peripheral neuropathy induced in mice by cisplatin: behavioral, structural and biochemical analysis.

Authors:  L Aloe; L Manni; F Properzi; S De Santis; M Fiore
Journal:  Auton Neurosci       Date:  2000-12-28       Impact factor: 3.145

3.  Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia.

Authors:  Tristan M Sissung; Klaus Mross; Seth M Steinberg; Dirk Behringer; William D Figg; Alex Sparreboom; Stephan Mielke
Journal:  Eur J Cancer       Date:  2006-09-06       Impact factor: 9.162

4.  Integrin beta-3 L33P: a new insight into the pathogenesis of chronic oxaliplatin-induced peripheral neuropathy?

Authors:  A G Antonacopoulou; A A Argyriou; C D Scopa; A Kottorou; A Kominea; S Peroukides; H P Kalofonos
Journal:  Eur J Neurol       Date:  2010-02-23       Impact factor: 6.089

Review 5.  Erythropoietin in cancer patients: pros and cons.

Authors:  Mario Dicato; Laurent Plawny
Journal:  Curr Opin Oncol       Date:  2010-07       Impact factor: 3.645

6.  Cisplatin-induced DNA-platination in experimental dorsal root ganglia neuronopathy.

Authors:  C Meijer; E G de Vries; P Marmiroli; G Tredici; L Frattola; G Cavaletti
Journal:  Neurotoxicology       Date:  1999-12       Impact factor: 4.294

7.  Cisplatin-induced apoptosis of DRG neurons involves bax redistribution and cytochrome c release but not fas receptor signaling.

Authors:  Elizabeth S McDonald; Anthony J Windebank
Journal:  Neurobiol Dis       Date:  2002-03       Impact factor: 5.996

8.  Oxaliplatin-induced lhermitte's phenomenon as a manifestation of severe generalized neurotoxicity.

Authors:  Susanna B Park; Cindy S-Y Lin; Arun V Krishnan; David Goldstein; Michael L Friedlander; Matthew C Kiernan
Journal:  Oncology       Date:  2009-12-14       Impact factor: 2.935

Review 9.  Chemotherapy-induced neuropathy.

Authors:  Anthony J Windebank; Wolfgang Grisold
Journal:  J Peripher Nerv Syst       Date:  2008-03       Impact factor: 3.494

10.  Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy.

Authors:  Paul G Richardson; Wanling Xie; Constantine Mitsiades; Asher A Chanan-Khan; Sagar Lonial; Hani Hassoun; David E Avigan; Anne Louise Oaklander; David J Kuter; Patrick Y Wen; Santosh Kesari; Hannah R Briemberg; Robert L Schlossman; Nikhil C Munshi; L Thompson Heffner; Deborah Doss; Dixie-Lee Esseltine; Edie Weller; Kenneth C Anderson; Anthony A Amato
Journal:  J Clin Oncol       Date:  2009-06-15       Impact factor: 44.544

View more
  110 in total

1.  Calcium and magnesium prophylaxis for oxaliplatin-related neurotoxicity: is it a trade-off between drug efficacy and toxicity?

Authors:  Guido Cavaletti
Journal:  Oncologist       Date:  2011-11-29

2.  The effect of curcumin on oxaliplatin and cisplatin neurotoxicity in rats: some behavioral, biochemical, and histopathological studies.

Authors:  Mansour S Al Moundhri; Suhail Al-Salam; Ahmed Al Mahrouqee; S Beegam; Badreldin H Ali
Journal:  J Med Toxicol       Date:  2013-03

3.  Identification of high-risk drugs related to chemotherapy-induced peripheral neuropathy in Cancer Therapy Evaluation Program-sponsored phase I trials.

Authors:  Shun Kishimoto; Nobu Oshima; Matthew Rinker; Murali C Krishna; Naoko Takebe
Journal:  Eur J Cancer       Date:  2019-05-24       Impact factor: 9.162

4.  Evidence that spinal astrocytes but not microglia contribute to the pathogenesis of Paclitaxel-induced painful neuropathy.

Authors:  Haijun Zhang; Seo-Yeon Yoon; Hongmei Zhang; Patrick M Dougherty
Journal:  J Pain       Date:  2012-01-29       Impact factor: 5.820

5.  HDAC6 inhibition effectively reverses chemotherapy-induced peripheral neuropathy.

Authors:  Karen Krukowski; Jiacheng Ma; Olga Golonzhka; Geoffroy O Laumet; Tanuja Gutti; John H van Duzer; Ralph Mazitschek; Matthew B Jarpe; Cobi J Heijnen; Annemieke Kavelaars
Journal:  Pain       Date:  2017-06       Impact factor: 6.961

6.  Polyester Nanoparticle Encapsulation Mitigates Paclitaxel-Induced Peripheral Neuropathy.

Authors:  R Ganugula; M Deng; M Arora; H-L Pan; M N V Ravi Kumar
Journal:  ACS Chem Neurosci       Date:  2019-01-17       Impact factor: 4.418

7.  Eg5 inhibitor, a novel potent targeted therapy, induces cell apoptosis in renal cell carcinoma.

Authors:  Sentai Ding; Zuohui Zhao; Dingqi Sun; Fei Wu; Dongbin Bi; Jiaju Lu; Naidong Xing; Liang Sun; Haihu Wu; Kejia Ding
Journal:  Tumour Biol       Date:  2014-05-07

Review 8.  Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention.

Authors:  Wolfgang Grisold; Guido Cavaletti; Anthony J Windebank
Journal:  Neuro Oncol       Date:  2012-09       Impact factor: 12.300

9.  Neuropeptide Y regulates the hematopoietic stem cell microenvironment and prevents nerve injury in the bone marrow.

Authors:  Min Hee Park; Hee Kyung Jin; Woo-Kie Min; Won Woo Lee; Jeong Eun Lee; Haruhiko Akiyama; Herbert Herzog; Grigori N Enikolopov; Edward H Schuchman; Jae-sung Bae
Journal:  EMBO J       Date:  2015-04-27       Impact factor: 11.598

10.  NON-INVASIVE EVALUATION OF NERVE CONDUCTION IN SMALL DIAMETER FIBERS IN THE RAT.

Authors:  Elena G Zotova; Joseph C Arezzo
Journal:  Physiol J       Date:  2013
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.